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The development of PTSD after military deployment is inﬂuenced by a combination of biopsychosocial
risk and resilience factors. In particular, physiological factors may mark risk for symptom progression or
resiliency. Research in civilian populations suggests elevated catecholamines after trauma are associated
with PTSD months following the trauma. However, less is known regarding physiological markers of
PTSD resilience among post-deployment service members (SM). We therefore assessed whether cate-
cholamines obtained shortly after deployment were associated with combat-related PTSD symptoms
three months later. Eighty-seven SMs completed the Clinician-Administered PTSD Scale for DSM-IV and
blood draws within two months after return from deployment to Iraq or Afghanistan (“Time 1” or “T1”)
and three months later (“Time 2” or “T2”). Linear regression analyses demonstrated that lower norepi-
nephrine at T1 was associated with lower PTSD symptoms at T2. In particular, T1 norepinephrine was
positively associated with T2 symptom intensity and avoidance symptoms. The present ﬁndings repre-
sent a biologically-informed method of assessing PTSD resilience after deployment, which may aid cli-
nicians in providing tailored treatments for those in the greatest need. Further research is needed to
validate these ﬁndings and incorporate physiological measures within an assessment battery.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Military service members (SM) deployed to wars in Iraq and
Afghanistan are more likely to experience posttraumatic stress
disorder (PTSD) symptoms related to both warzone and homefront
experiences (Smith et al., 2008; Vasterling et al., 2010) than those
who did not deploy. Post-deployment PTSD symptoms are associ-
ated with reduced quality of life and functional status in SMs
(Schnurr et al., 2009; Tsai et al., 2012), even for those whose
symptoms fall short of meeting full diagnostic criteria for PTSD
(Cukor et al., 2010; Grubaugh et al., 2005; Magruder et al., 2004).
The current literature implies a variable risk for PTSD symptom
development, attributable to a number of risk (e.g. number of, Department of Medicine,
. Highland).
Inc. This is an open access article udeployments, traumatic brain injury, combat exposure, genetics)
and resilience (e.g. unit support, post-deployment social support)
factors (Hoge et al., 2008; Pietrzak et al., 2010; Reger et al., 2009;
Seal et al., 2009; Skelton et al., 2012). However, less attention has
been given to physiological factors that may signal risk for symp-
tom progression, or conversely, the potential for resilience, after
deployment, particularly with respect to subthreshold PTSD.
The catecholamines dopamine (DA), epinephrine (EPI), and
norepinephrine (NE) are monoamines that are produced both
within the central nervous system, where they act as neurotrans-
mitters that are released to facilitate adaptive responses to acute
stressors (Cahill and Alkire, 2003; Southwick et al., 2002), as well as
in the sympathoadrenal system where they regulate physiologic
responses to stressors. While beneﬁcial in acute stress, repeated
activation in chronic stress leads to dysregulation of catecholamine
release, and increases the risk of PTSD; whereas adaptive cate-
cholamine responses may signal resilience (Krystal andnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Total, intensity, frequency, and cluster CAPS scores across time points.
T1 mean (SD) T2 mean (SD) t (p)
Dopamine 28.64 (16.05) 28.67 (16.03) .26 (.79)
Epinephrine 51.20 (25.57) 61.01 (36.43) 1.44 (.16)
Norepinephrine 274.77 (173.50) 309.67 (215.32) 1.18 (.25)
Total CAPS 19.6 (12.8) 15.4 (15.1) 2.32 (.02)
CAPS e intensity 7.7 (5.4) 6.1 (6.04) 1.99 (.05)
CAPS e frequency 12.0 (7.6) 9.1 (9.0) 2.56 (.01)
CAPS e re-experiencing 4.3 (4.3) 2.02 (3.7) 3.65 (.001)
CAPS e avoidance 4.9 (4.94) 4.4 (6.5) .62 (.54)
CAPS e hyperarousal 10.5 (6.4) 8.9 (7.5) 1.65 (.11)
Note: CAPS: Clinician Administered PTSD Scale.
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sponses may dictate physiological reactions, but physiological re-
actions may also lead to psychological effects. Basal catecholamine
levels have been associated with PTSD in a community sample
(Young and Breslau, 2004), and there is some evidence that
neuroendocrine measures (e.g. cortisol and NE) may be linked with
trauma-related symptoms in adults within two months after
trauma (Delahanty et al., 2000). Findings also indicate that cate-
cholamine elevations can persist longer than 6 months given psy-
chopathology. For example, combat veterans with chronic PTSD
have higher baseline cerebral spinal ﬂuid NE concentrations under
unstressed conditions than their counterparts without PTSD
(Geracioti et al., 2001). Furthermore, recent work suggests that
variants of the gene coding for catechol-O-methyl transferase, an
enzyme involved in catecholaminemetabolism, are associated with
PTSD (Kolassa et al., 2010; Norrholm et al., 2013).
Building upon these studies, we hypothesized that basal cate-
cholamine levels obtained shortly after return from deployment
could further improve our ability to predict resilience against
combat-related PTSD symptoms in the subsequent months. We
therefore compared catecholamine levels obtained within two
months after return from deployment (T1) with PTSD symptoms
three months later (T2). We expected that lower levels of DA, EPI,
and NE at T1 would be associated with less severe PTSD symptoms
at T2. Given that psychological states can induce changes in cate-
cholamine systems, we also examined the reverse relationship,
anticipating that lower T1 PTSD symptoms would be associated
with lower catecholamine levels at T2.
2. Methods
2.1. Participants and procedure
SMs (N ¼ 87) were recruited either through institutional review
board-approved advertisements, or via direct contact immediately
upon their return to the U.S. during postdeployment demobiliza-
tion procedures at Fort Dix, NJ. Their current duty stations spanned
the United States. They completed a T1 assessment within two
months of return from deployment to Iraq or Afghanistan and then
again three months later (T2). Inclusion criteria included the ability
to complete informed consent, a structured interview, and a
morning blood draw. Participants screening positive for probable
PTSD (PTSD Checklist score  50), major depression (Patient Health
Questionnaire-9 score  10), or post-concussive syndrome at
baseline were excluded. Further exclusionary criteria included
having a history of head injury resulting in a loss of consciousness
for 60 minutes or more, a current Glasgow Coma Scale of less than
14 points, active psychotic symptoms, or active suicidal or homi-
cidal ideation. Participants on alpha blockers or calcium channel
blockers were excluded if they were unable to hold these medica-
tions for a 24-hour period preceding brain imaging scans. Combat-
related PTSD symptoms were assessed by a trained, PhD-level
psychologist using the Clinician-Administered PTSD Scale for
DSM-IV (CAPS, Blake et al., 1995; Weathers et al., 2001), with
traumatic events including improvised explosive devices, ﬁreﬁght,
vehicular accidents, and other combat-related traumas. The fre-
quency and intensity of each symptom cluster (e.g. re-experiencing,
avoidance, hyperarousal) were combined to create a total score.
Blood draws occurred prior to 0900. Plasma samples were iso-
lated from whole blood in sodium heparin preserved collection
tubes with centrifugation for 10 minutes at room temperature.
Samples were stored at 70 C and run in a single batch. A
commercially available Enzyme Immunoassay measured plasma
catecholamine (EPI, NE, DA) levels, using Alpco Diagnostics (Salem,
NH) Tri-Cat assay (17-TCTHUE03-RES).2.2. Data analysis
First, step-wise linear regressions assessed whether T1 cate-
cholamine levels were associated with T2 CAPS scores. Age, gender,
and T1 CAPS score served as control variables. Catecholamine levels
(DA, EPI, and NE) were entered as independent predictors. Both
controls and predictors were entered in a step-wise fashion. The
corresponding T2 CAPS score was analyzed as the dependent var-
iable. T2 analyses modeled CAPS frequency and intensity, and CAPS
symptom clusters, separately. Additional analyses were conducted
to determine whether the reverse relationship was supported, such
that T1 CAPS scores were associated with catecholamine levels at
T2 when controlling for T1 catecholamine levels.
3. Results
Reﬂecting the overall deployed population, study participants
were predominantly male (85%), single (53%), Caucasian (73%), and
employed (71%). On average, participants were 30.0 (SD ¼ 8.0)
years old, had served 9.4 (5.9) years in the military, and had been
deployed 1.7 (SD ¼ 1.0) times since 2001. Total CAPS scores
decreased from T1 to T2. In particular, symptom frequency and re-
experiencing symptoms showed signiﬁcant decreases between
time points. Catecholamine levels and CAPS scores are shown in
Table 1. There were no signiﬁcant correlations between T1 cate-
cholamine levels and T1 CAPS scores. The correlations between T1
variables, as well the correlations among T1 and T2 variables, are
shown in Table 2.
In order to examine the relationship betweenT1 catecholamines
and PTSD symptomatology at T2, we completed step-wise linear
regressions, while adjusting for T1 PTSD symptomatology. When
controlling for T1 CAPS scores, step-wise linear regressions
demonstrated that T1 NE was predictive of PTSD symptomatology
at T2, in as much as T1 NE (b ¼ .28, SE ¼ .01, p ¼ .03) was positively
associated with T2 total CAPS scores (see Fig. 1). T2 step-wise linear
regressions examined whether this association was due to symp-
tom frequency or intensity. T1 NE levels (b¼ .32, SE¼ .004, p¼ .02)
were associated with T2 CAPS intensity but not CAPS frequency. For
these regressions, age, gender, and other catecholamines were not
included in the ﬁnal models as they were not signiﬁcantly associ-
ated with T2 CAPS scores.
Next, step-wise linear regressions examined whether T1 cate-
cholamine levels were associated with particular CAPS symptom
clusters. T1 catecholamines were not associated with re-
experiencing or hyperarousal at T2. However, T1 NE was posi-
tively associated with T2 avoidance scores (b ¼ .38, SE ¼ .004,
p ¼ .01). In particular, NE was positively associated with T2
avoidance frequency (b ¼ .36, SE ¼ .002, p ¼ .006) and intensity
(b ¼ .38, SE ¼ .002, p ¼ .007). As noted in the previous step-wise
regressions, age, gender, and other catecholamines were not
retained in any of the ﬁnal models.
Table 2
Correlations among catecholamine levels and PTSD symptoms, with correlations among T1 variables shown below the diagonal and correlations between T1 with T2 variables
shown above the diagonal.
1. 2. 3. 4. 5. 6. 7. 8. 9.
1. Dopamine .19 .02 .02 .02 .04 .04 .07 .004
2. Epinephrine .001 .05 .24 .26 .22 .07 .29* .20
3. Norepinephrine .08 .24* .13 .18 .10 .06 .19 .13
4. Total CAPS .001 .07 .18 .46** .52** .32* .32* .59**
5. CAPS e intensity .04 .10 .17 .98** .49** .27** .31* .56**
6. CAPS e frequency .04 .07 .19 .98** .93** .25 .08 .40**
7. CAPS e re-exper. .24* .04 .12 .80** .78** .79** .44** .37**
8. CAPS e avoidance .26* .09 .16 .74** .74** .71** .38** .59**
9. CAPS e hyperarousal .04 .10 .15 .89** .85** .89** .63** .45**
Note: CAPS ¼ Clinician Administered PTSD Scale, re-exper. ¼ re-experiencing.
**p < .01, *p < .05.
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mine whether the reverse relationship was supported, such that T1
CAPS scores were associated with catecholamine levels at T2. In
each of these analyses, the CAPS total score, frequency score, and
intensity score were not associated with T2 catecholamine levels,
when controlling for T1 catecholamine levels. When examining
CAPS symptom clusters separately, T1 avoidance was associated
with T2 DA levels (b ¼ .40, SE ¼ .63, p ¼ .04).4. Discussion
We found that lower blood NE levels obtained within two
months after return from deployment were associated with lower
combat-related PTSD symptoms three months later. In particular,
T1 NEwas positively correlatedwith overall symptom intensity and
avoidance symptoms at T2. Avoidance is most strongly associated
with reduced functioning among SM deployed to Iraq and
Afghanistan (Rona et al., 2009; Sayers et al., 2009), therefore
identifying a biomarker of resilience may be especially important
when developing treatments focused on promoting recovery after
deployment.
Elevated NE activity has been associated with both PTSD
(Pietrzak et al., 2013), and with enhancement of memory consoli-
dation in emotionally arousing situations in those with PTSD
(Southwick et al., 2002). Increased NE can also result in heightened
arousal and nightmares in PTSD patients, and prazosin, a post-
synaptic a1-adrenergic receptor antagonist, has been shown to be
a successful therapy for this element of combat-related PTSD
(Raskind et al., 2013). Other studies have found mixed results when
assessing psychopharmacological NE interventions (Steckler and
Risbrough, 2012). For example, propranolol, a b-adrenergic antag-
onists that blocks post-synaptic NE receptors, has not been shown
to reduce PTSD symptoms or the likelihood of a PTSD diagnosis
when administered acutely after traumatic events (Hoge et al.,
2012; Stein et al., 2007) Furthermore, clonidine, a a2-adrenergic
receptor agonist, has been shown to reduce hyperarousal symp-
toms among individuals who have comorbid PTSD and borderline
personality disorder (Ziegenhorn et al., 2009); whereas guanfacine,
an a2-adrenergic receptor agonist, has been shown to have no ef-
fect on chronic PTSD among veterans (Neylan et al., 2006). The
difference between the two studies' ﬁndings may be due to
participant characteristics, comorbidities, sample sizes, or the
medications themselves, despite having similar functioning. Our
results are consistent with previous ﬁndings showing that NE and
cortisol levels, measured acutely after trauma, are predictive of
subsequent PTSD symptoms (Delahanty et al., 2000). Interestingly,
a study involving treatment for complicated grief also found that
individuals with lower basal NE levels had the lowest post-therapy
complicated grief symptoms, even when controlling for T1symptoms (O'Connor et al., 2013).
We found evidence that T1 PTSD symptoms are associated with
subsequent catecholamine levels three months later. Lower T1
avoidance scores were associated with reductions in DA at T2.
Dopaminergic systems have been associated with avoidance
learning (Frank and Hutchison, 2009), whereas administration of a
dopamine agonist (pramipexole) has been shown to diminish
reinforcement-related behaviors in healthy participants (Pizzagalli
et al., 2008). In the present ﬁndings, successful avoidance of
trauma-related stimuli may enable avoidance learning. Across time,
the act of avoidance may become physiologically reinforcing, even
if an immediate perceived threat is not present. Historically, animal
studies demonstrate the role of NE in avoidance. In the amygdala,
NE increases during unconditioned stress (Heinsbroek et al., 1990;
Tanaka et al., 2000), which in turn is associated with enhanced
avoidance learning retention and avoidance behaviors in rats (Gold
and van Buskirk, 1978; Tanaka et al., 2000). Taken together, the
present ﬁndings demonstrate a bidirectional relationship between
symptomology and physiology, an improved understanding of
which may help identify individuals who experience sub-threshold
combat-related PTSD symptoms in the months following return
from deployment.
The present study possesses a number of strengths including the
use of longitudinal data, analyses assessing for bi-directional re-
lationships between variables, and exploration of individual
symptom clusters, which may facilitate the development of novel
therapies (Norrholm and Jovanovic, 2010). Exploration of the bio-
logical underpinnings of symptom severity has been highly advo-
cated by the National Institutes of Health (Insel et al., 2010). The
current study provides markers of resilience that are independent
of DSM diagnostic criteria. Moreover, our timeline focused on the
acute post-deployment period, a window of time which can set the
course for future combat-related PTSD symptoms, and provides the
potential for early intervention.
There are also some limitations to be acknowledged. The time
course of combat-related PTSD symptoms may follow a variety of
trajectories which may not be captured by only assessing two
points in time. Second, we cannot rule out common precursors or
mediating factors that may serve to link PTSD symptoms and
catecholamine function and future studies would beneﬁt from the
addition of a non-deployed control group to determine the unique
contributions of combat-related trauma in the relationship be-
tween symptoms and catecholamine function. Third, although our
ﬁrst time point is shortly after deployment, the deployment
experience is highly variable, and some may have experienced
signiﬁcant traumas early in their deployment, so that nearly a year
may have already passed by this point for some individuals. Fourth,
we did not exclude individuals taking psychotropic medications
that may affect catecholamine levels, future research would beneﬁt
Fig. 1. Relationship between T1 norepinephrine levels and T2 total CAPS score when
controlling for T1 total CAPS score.
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in deliberately focusing on a sample with subthreshold symptoms,
wemay be elucidating patterns predictive of recovery more so than
PTSD.
Risk stratiﬁcation is the ﬁrst step toward reducing PTSD symp-
toms in SMs who have been deployed. Recent evidence suggests
early evidence-based intervention after a trauma may reduce the
adverse effect of biological risk factors (Rothbaum et al., 2014).
Within a clinical context, biological markers help elucidate a more
detailed proﬁle of functioning and help ﬁll in gaps where self-
report accuracy declines in the face of recall bias, symptom mini-
mization, and alexithymia. As such, these markers could be used to
identify those in need of more intense treatment or resiliency
training prior to meeting clinical criteria for PTSD, thereby pre-
venting progression to a PTSD diagnosis.
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